Each one in plain English, with the numbers worked through for a shareholder.
12 Aug 2026capital raising announcement● NeutralMajor
Elixir raised $5M via a placement of 125M shares at $0.04, a 20% discount to the $0.05 close. Funds go to the Lorelle-3H soak and retest, Diona-1 artificial lift (subject to JV approval) and a newly launched strategic review of options including farm-outs.
What it means for a shareholder
125m new shares at A$0.040 to raise about A$5.0m. That's 6.3% dilution: every existing holder's slice gets 6.3% smaller. If you held A$1,000 of shares (25,000 at the issue price), your slice goes from 0.00134% to 0.00125% of the company. To keep it you'd need 1,672 more shares - about A$67 at the issue price.
25 Nov 2025capital raising announcement▲ GoodMajor
Omega Oil and Gas will take 19.43% of Elixir at 4.1c per share, investing up to $14.6M. Nero adds $2M, for about $16.6M total. Funds a Lorelle-3 horizontal sidetrack and Diona-1 testing; pro-forma cash is about $25M. Tranche 2 needs shareholder approval.
Omega's side of the deal: it buys 19.43% of Elixir at 4.1c per share, $13.9M in an unconditional first tranche. It gains up to two board seats, participation rights and a technical committee. Duplicates Elixir's own announcement from the investor's perspective.
The share purchase plan closed with only $117,000 of applications against up to $2M sought, taking the placement plus plan total to $7.1M. Cash plus receivables, including a $3.7M R&D refund, total $10.6M at end of April.
Elixir extended its share purchase plan (3.5c shares, one free 12c option per two shares) to close on 29 April 2025 and deferred the general meeting to 23 April. It tied the extension to new CEO Stuart Nicholls and a share price of about 3 cents.
Prospectus for the shareholder purchase plan: up to 57.1M shares at 3.5c to raise up to $2.0M, with up to 28.6M free 12c options. Not underwritten and subject to shareholder approval. The 199.5M placement shares were issued 17 February.
What it means for a shareholder
57.1m new shares at A$0.035 to raise about A$2.0m. That's 3.9% dilution: every existing holder's slice gets 3.9% smaller. If you held A$1,000 of shares (28,571 at the issue price), your slice goes from 0.00205% to 0.00197% of the company. To keep it you'd need 1,168 more shares - about A$41 at the issue price.
Timetable for the $2M shareholder purchase plan at 3.5c, with one free 12c option per two shares and a $30,000 cap per holder. It closes 15 April, subject to approval at a 23 April meeting. This follows the 11 February placement.
Section 708A cleaning notice for the 25 July placement: 62.5M shares, 15.6M placement options and 3.1M broker options issued on 31 July. Administrative. The notice also contains an apparent typo of 262.5M shares.
25 July 2024capital raising announcement● NeutralMajor
Elixir raised $6.25M via a placement of 62.5M shares at 10c, a 13% discount to last close, with one EXROB option (12c, expiring Oct 2026) per four shares. Funds cover Daydream-2 contingencies, long-lead items for the next well and farm-out negotiating strength.
What it means for a shareholder
62.5m new shares at A$0.100 to raise about A$6.3m. That's 5.2% dilution: every existing holder's slice gets 5.2% smaller. If you held A$1,000 of shares (10,000 at the issue price), your slice goes from 0.000882% to 0.000836% of the company. To keep it you'd need 551 more shares - about A$55 at the issue price.
13 Dec 2023capital raising announcement● NeutralMajor
Elixir raised $6.5M via a placement of about 76M shares at 8.5c, a 15% discount to last close, with one listed option (12c, expiring Oct 2026) per three shares. Funds mainly expand Daydream-2 stimulation and testing. No SPP offered, as one ran under 3 months ago.
What it means for a shareholder
76.0m new shares at A$0.085 to raise about A$6.5m. That's 6.7% dilution: every existing holder's slice gets 6.7% smaller. If you held A$1,000 of shares (11,765 at the issue price), your slice goes from 0.00112% to 0.00104% of the company. To keep it you'd need 848 more shares - about A$72 at the issue price.
10 Oct 2023capital raising announcement● NeutralMajor
The Share Purchase Plan raised $1.725M at 7c, below the $3.5M target, bringing the total with the placement to $8.7M. Issue is conditional on AGM approval on 16 October. Funds go to Daydream-2, Nomgon and working capital.
The Share Purchase Plan opened, offering up to $3.5M at 7c with free attaching options. The Board may take an extra $2M or scale back applications. Closes 6 October; conditional on shareholder approval at the 16 October AGM.
Shareholder letter delivering the Share Purchase Plan offer: up to $30,000 at 7c, free attaching options, closing 6 October. Repeats the terms announced earlier; no new information.
Prospectus lodged for the Share Purchase Plan: up to $30,000 per eligible holder at 7c, with one free 12c option per two shares, expiring 17 October 2026. Offer closes 6 October. The SPP and options need shareholder approval at the AGM around 16 October.
29 Aug 2023capital raising announcement● NeutralMajor
Elixir raised about $7.0M through a placement of ~100M shares at 7c, a 14.6% discount to last close, with one 12c option per two shares. A Share Purchase Plan of up to $3.5M follows at the same price. Funds Daydream-2 and Nomgon; the R&D rebate is now stated as 48.5%, up from 43.5%.
What it means for a shareholder
100m new shares at A$0.070 to raise about A$7.0m. That's 9.7% dilution: every existing holder's slice gets 9.7% smaller. If you held A$1,000 of shares (14,286 at the issue price), your slice goes from 0.00153% to 0.00138% of the company. To keep it you'd need 1,533 more shares - about A$107 at the issue price.
12 May 2021capital raising announcement▲ GoodMajor
The Share Purchase Plan closed having raised $16.6m from over 1,400 shareholders, below the $20m target. With the $10m placement, the 36c raising totals about $26.6m, completing the funding for the expanded program.
Offer booklet for the Share Purchase Plan: eligible holders can apply for $500 to $30,000 of shares at 36c, closing 7 May 2021, with new shares to trade from 19 May. Terms repeat the 21 April announcement.
Elixir raised $10m through a placement of 27.8m shares at 36c, a 20% discount to the last close. It also launched a Share Purchase Plan targeting $20m at the same price. The money funds an expanded Mongolian program meant to bring development forward 18-24 months.
What it means for a shareholder
27.8m new shares at A$0.360 to raise about A$10.0m. That's 3.3% dilution: every existing holder's slice gets 3.3% smaller. If you held A$1,000 of shares (2,778 at the issue price), your slice goes from 0.000341% to 0.00033% of the company. To keep it you'd need 95 more shares - about A$34 at the issue price.
The final 5,949,622 listed options were exercised at 6.79c, raising $403,979; 392,424 expired unexercised on 31 December. Shares on issue are about 810.0m. The option exercise campaign closes having raised about $8.02m in total.
10,096,906 listed options exercised at 6.79c, raising $685,580. Shares on issue rise to about 804.0m, with about 6.3m options left on the final day. Total raised from exercises is about $7.62m.
23,128,772 listed options exercised at 6.79c, raising $1,570,444. Shares on issue rise to about 794.0m, with about 16.4m options left. Total raised from exercises is about $6.93m. Option trading on ASX has stopped ahead of expiry.
20,827,365 listed options exercised at 6.79c, raising $1,414,178. Shares on issue rise to about 770.8m, with about 39.6m options left before 31 December expiry. Total raised from exercises is about $5.39m.
1,650,914 listed options exercised at 6.79c, raising $112,097. Shares on issue rise to about 750.0m, with about 60.4m listed options left before expiry on 31 December 2020. Total raised from exercises is about $3.95m.
15,104,593 listed options were exercised at 6.79c, raising $1,025,602. Shares on issue rise to about 748.3m, with about 62.0m listed options remaining before expiry on 31 December 2020. Total raised from option exercises reaches about $3.8m.
12,457,193 listed options were exercised at 6.79c, raising $845,843. Shares on issue rise to about 733.2m, with about 77.2m listed options remaining before expiry on 31 December 2020. Exercise pace is accelerating.
3,509,269 listed options were exercised at 6.79c, raising $238,279. Shares on issue rise to about 720.8m, with about 89.6m listed options remaining until expiry on 31 December 2020. Steady exercises continue.
4,658,706 listed options were exercised at 6.79c, raising $316,326. Shares on issue rise to about 717.3m, with about 93.1m listed options remaining before expiry on 31 December 2020.
4,451,660 listed options were exercised at 6.79c, raising $302,268. Shares on issue rise to about 712.6m, with about 97.8m listed options remaining until expiry on 31 December 2020. Exercises are picking up.
353,460 listed options were exercised at 6.79c, raising $24,000. Shares on issue rise to about 708.2m, with about 102.2m listed options left before expiry on 31 December 2020. Very small sum.
4,701,000 listed options were exercised at 6.79c, raising $319,197. Shares on issue rise to about 707.8m, with about 102.6m listed options remaining until they expire on 31 December 2020. Continues the steady option exercises.
